Pancreatic Cancer Research

ResearcherUniversité Paris CitéActive in the last 2 years

Olivia Hentic Dhome

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-5402-8797; OpenAlex author ID A5008482986. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers

Papers 10

  1. Distal pancreatectomy with celiac axis resection (DP-CAR) for pancreatic ductal adenocarcinoma in a retrospective monocentric cohort: neoadjuvant treatment and… Co-author DOI 10.1016/j.hpb.2025.04.009↗
  2. Laparoscopic pancreatoduodenectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared with open pancreatoduode… Co-author DOI 10.1016/j.surg.2024.09.041↗
  3. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  4. Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. Co-author DOI 10.1177/17588359231163776↗
  5. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.05.006↗
  6. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  7. Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database. Co-author DOI 10.1097/meg.0000000000000901↗
  8. [Pancreatic adenocarcinoma: 10 years of progress]. Last author DOI 10.1016/s0007-4551(15)31219-4↗
  9. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  10. Gemcitabine in elderly patients with advanced pancreatic cancer. Co-author DOI 10.3748/wjg.v17.i30.3497↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vinciane Rebours · 4 shared papers, 2021–2025 · strength 0.80
  2. Louis de Mestier · 4 shared papers, 2015–2025 · strength 0.59
  3. Alain Sauvanet Sauvanet · 3 shared papers, 2019–2025 · strength 0.59
  4. Safi Dokmak · 2 shared papers, 2025 · strength 0.51
  5. Mickaël Lesurtel · 2 shared papers, 2025 · strength 0.51
  6. Pascal R. Hammel · 4 shared papers, 2015–2023 · strength 0.41
  7. Elias Karam · 1 shared paper, 2025 · strength 0.27
  8. Maxime Ronot · 1 shared paper, 2025 · strength 0.25
  9. Jerome F. Cros · 1 shared paper, 2025 · strength 0.25
  10. Thibaud Bertrand · 1 shared paper, 2025 · strength 0.25
  11. Romain Coriat · 3 shared papers, 2015–2021 · strength 0.24
  12. Thomas Chaigneau · 1 shared paper, 2023 · strength 0.16
  13. Lina Aguilera Munoz · 1 shared paper, 2023 · strength 0.16
  14. Flore Pignon · 1 shared paper, 2021 · strength 0.12
  15. Anthony Turpin · 1 shared paper, 2021 · strength 0.12
  16. Daniel Pietrasz · 2 shared papers, 2015–2019 · strength 0.12
  17. Olivıer Turrini · 2 shared papers, 2015–2019 · strength 0.12
  18. Christophe Laurent · 2 shared papers, 2015–2019 · strength 0.12
  19. António Sá Cunha · 2 shared papers, 2015–2019 · strength 0.12
  20. Julien Taı̈eb · 2 shared papers, 2015–2019 · strength 0.12
  21. Jean‐Baptiste Bachet · 2 shared papers, 2015–2019 · strength 0.12
  22. V. Vendrely · 1 shared paper, 2019 · strength 0.07
  23. Jean‐Robert Delpéro · 1 shared paper, 2019 · strength 0.07
  24. F. Huguet · 1 shared paper, 2019 · strength 0.07
  25. Fabienne Portales · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.